

France Biotech is delighted with the success of the first edition of the HealthTech Investor Days (HTID®) on June 24th & 25th in Paris

- 500 international actors in Health innovation financing present in Paris
- A business opportunity for key players of the European ecosystem of health innovation: more than 900 formal and informal meetings between European HealthTech companies, international investors and healthcare industry groups
- An institutional evening reception at the *Hôtel de Matignon (French Prime Minister's office)*, showing strong support from government for this initiative
- HTID is now positioned as a new annual event for HealthTech's future European unicorns to accelerate their growth. Following the enthusiasm for this first event, a new edition is already scheduled on June 22nd & 23rd 2020.

Paris, July 4th, 2019 – **France Biotech**, the main professional association representing French health entrepreneurs and organizer of the **HealthTech Investor Days**, is delighted with the success of this first edition. With 500 registered participants over two days, 90 European HealthTech companies, the same number of international investors, 15 pharmaceutical companies and 50 international experts, the enthusiasm generated around this European event exceeded the organizers' expectations.

"It's a real success and a winning bet," explains Maryvonne Hiance, Chairman of France Biotech. *"What we lacked in Europe was a privileged space for meetings and discussions between companies responding to the health issues of tomorrow, and organizations capable of funding them! We are delighted with the success and enthusiasm generated by this first edition. We keep receiving a lot of support and appreciation from the participants since its closing."*

The originality of the HTID is to offer a business opportunity in Europe for the actors of the European ecosystem of health innovation: over two days the event has generated nearly 900 formal and informal meetings between European HealthTech companies, international investors and industrial health groups. These contacts will lead to industrial partnerships and financial support in the long term. In this respect, the HealthTech Investor Days is a growth accelerator enabling some of the most promising European start-ups to develop their products more quickly and make them available to patients as soon as possible thanks to adequate funding.

"The key to this success is the participation of international investors," says Maryvonne Hiance. Nearly half of the investors present at this first edition came from outside of France (China, United States, Singapore, Israel, ...), among which large funds such as Orbimed, Temasek, Cathay Capital, ...

Strong support from European and French institutions

Placed under the High Patronage of the President of the French Republic, **Mr. Emmanuel MACRON**, and supported by the Minister of Economy and Finance, Bruno LE MAIRE, the HTID has received a warm welcome from the French government. An institutional reception was organized on the evening of June 24th at the *Hôtel de Matignon (Prime Minister's office)*, with the presence of the Secretary of State

Agnès Pannier Runacher and a delegation of HTID participants (leaders of European HealthTech companies, international investors, etc.) illustrating the commitment of public authorities for this initiative launched by France Biotech.

The European attractiveness highlighted by the HTID has been echoed equally favorably by the European institutional ecosystem. The attendance of the Head of the representation of the European Commission in France, Isabelle JEGOUZO, as well as representatives of the European Investment Bank, or European associations such as EuropaBio, EIT Health, EBE (European Biopharmaceutical Enterprises) or IREFI (Economic Institute for France Italy Relations) is only one example of the mobilization of the European ecosystem around the HTID.

A date already set for the second edition in 2020!

Building on the success of this first edition, France Biotech and its partners have already scheduled the second session of the HTID which will be held on June **22nd & 23rd 2020 in Paris**. *"We want to continue this good momentum at the next HTID! We thank all participants and partners and invite them to the next edition in 2020. We hope that it will be marked by an even greater participation of foreign investors and discussions as qualitative and numerous "* concludes Maryvonne Hiance.

The **HealthTech Investor Days** is now one of the key annual events in Europe for health innovation financing.

What participants think of this event...

Filippo Petti, CEO of Ceylad: *"We are delighted to have participated to this 1st edition of the HTID. As a Belgian company, we can only applaud the support given by the French government to the European health ecosystem. In addition to bringing together the best companies in the sector and specialized investors, this event brings high visibility on a sector creating direct and indirect qualified jobs. Gathering all actors in this value chain can only be virtuous, allowing academic research to find an industrial outlet. "*

Nawal Ouzren, CEO of Sensorion: *"Being part of France Biotech's Board, I had the opportunity to follow this project from its birth and see it grow into an exceptional event that has successfully united and federated the HealthTech ecosystem. The work done by France Biotech generated a lot of enthusiasm and brought high quality investors and pharmaceutical companies."*

Corinne Blachier-Poisson, Chairman of Amgen France: *"It was great to attend and support HTID's first edition. As the only American pharma company partner, this event was the opportunity for us to formalize our desire to invest in innovation in France and increase our synergies with many start-ups. Amgen's American and European representatives came away very impressed by the French ecosystem's richness. France is definitely a center of excellence in e-health, artificial intelligence and big data but also in biotech start-ups. We hope to be there next year with possible new partners and wish to be even more involved in the French innovation ecosystem."*

About France Biotech

Created in 1997, France Biotech is a French nonprofit organization that brings together the country's leading innovative health companies and their expert partners (investors, lawyers, research institutes, clusters, etc.). Its core mission is to promote health innovation in France and help the sector's start-up companies and SMEs to become successful organizations, capable of rapidly developing new therapeutic solutions. France Biotech is chaired by Maryvonne Hiance and has over two hundred members. www.france-biotech.fr

Press contacts

ALIZE RP - Europe

Caroline Carmagnol / Tatiana Vieira

francebiotech@alizerp.com

+336 64 18 99 59 / +336 47 38 90 04 / +336 31 13 76 20

RooneyPartners LLC – North America

Marion Janic / Kate Barrette

mjanic@rooneyco.com / kbarrette@rooneyco.com

+1.212.223.4017 / +1.212.223.0561

France Biotech

Maryvonne Hiance

Chairman

mhiance@france-biotech.org